Relapsing-Remitting Multiple Sclerosis Clinical Trial
— COASTOfficial title:
A Randomised Controlled Trial to Compare Ocrelizumab or Alemtuzumab With Autologous Hematopoietic Stem Cell Transplantation (aHSCT) in High Inflammatory Multiple Sclerosis (COAST)
Verified date | March 2022 |
Source | Universitätsklinikum Hamburg-Eppendorf |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A multicentre controlled phase II trial to compare the efficacy and safety of ocrelizumab or alemtuzumab and autologous Hematopoietic Stem Cell Transplantation (aHSCT). Active relapsing-remitting MS-Patients will be included and randomised to ocrelizumab or alemtuzumab versus aHSCT. Primary endpoint will be the time to treatment failure as assessed by failure of NEDA (no evidence of disease activity) as represented by: no expanded disability status scale (EDSS) progression, no relapse, no new T2 lesion and no Gd-enhancing lesion. This trial offers the opportunity to gain further information about efficacy and safety of all treatments and will give new insights into the immunology of highly active RRMS.
Status | Terminated |
Enrollment | 1 |
Est. completion date | February 4, 2022 |
Est. primary completion date | February 4, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria (Based on CARE-MS-II3, guidelines and Rio-criteria for treatment failure): - Written informed consent and agreement to comply to study protocol - Age: 18-55 years - EDSS: 0.0 - 6.0 - RRMS according to McDonald 2010 - < 10 years of disease course after symptom onset - Active disease with one of the following treatment failures occur-ring not earlier than 6 months after initiation of an approved DMT - 2 or more relapses within the last 12 months or - 1 relapse within the last 12 months and a Gd-enhancing lesion on MRI > 3 mm > 3 months before or after relapse onset or 2 new T2-lesions or - On-going signs of MRI activity in the last 6 months (either Gd-en-hancing of = 3 mm lesion at any exam in the last year; or more than 5 new T2 lesions (= 3 mm) or - Patients stable under natalizumab but who have to stop treatment due to an increasing PML risk are defined as active, if a MRI within 6 months after termination of natalizumab shows new T2 or Gd-enhancing lesions and at least one other treatment fail-ure prior to natalizumab is documented. Exclusion Criteria: - Secondary or primary progressive MS - Pregnancy, or other medical condition incompatible with aHSCT - Any treatment or medical condition that, according to the haematologist / transplant specialist precludes the use of aHSCT - John Cunningham virus (JCV) antibody index of > 1.5 in previ-ously natalizumab-treated patients, if a negative CSF JCV-PCR prior to screening is not available - Relapse during 30 days before initiation of treatment. If a relapse occurs during this period and eligibility criteria are otherwise ful-filled, start of treatment will be delayed until at least 30 days after receiving steroids. - Concurrent clinically significant (as determined by the investiga-tors and haematologist / transplant specialist) cardiac, immuno-logical, pulmonary, neurological, renal or other major disease such as: - Prominent cardial disease (Left ventricular ejection frac-tion (LVEF) < 40%, myocardial infarction or ischemia, un-controlled arrhythmias, pericardial effusion > 1 cm) - Cerebrovascular disease - Renal disease (creatinine clearance < 30 ml/min/m2) - Respiratory disease (DLCO < 40% predicted) - Active bleeding or clotting disease - History of human immunodeficiency virus (HIV) or posi-tive HIV antibody testing - Any uncontrolled acute or chronic infection, including HIV, hepatitis B surface antigen positivity and hepatitis C PCR positivity - Cancer except in situ cervix or cutaneous - Unwillingness or inability to comply with the requirements of this protocol including the presence of any condition (physical, men-tal, or social) that is likely to affect the patient returning for follow-up visits on schedule. Unwillingness to use contraception. - Previous participation in this study, previous treatment with aHSCT or already both comparators - Ongoing immunotherapy. Treatment with interferon or glati-rameracetate will need no wash-out. Treatment pause before oc-relizumab/alemtuzumab or aHSCT will be: - for dimethylfumarate and fingolimod: 8 weeks - for natalizumab: 8 weeks - for ocrelizumab: 12 weeks - for alemtuzumab: 12 months - for teriflunomide: 4 weeks after elimination with cholesty-ramine - for cladribine: 24 weeks - Patients with cognitive impairments who are unable to provide written, informed consent prior to any testing under this protocol, including screening and baseline investigations that are not con-sidered part of routine patient care. |
Country | Name | City | State |
---|---|---|---|
Germany | Universitätsklinikum Hamburg-Eppendorf | Hamburg | |
Germany | Universitätsklinikum Mannheim | Mannheim |
Lead Sponsor | Collaborator |
---|---|
Universitätsklinikum Hamburg-Eppendorf | Clinical Trial Center North (CTC North GmbH & Co. KG), Neovii Biotech |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to treatment failure as assessed by failure of NEDA (no evidence of disease activity) | Time to treatment failure as assessed by failure of NEDA (no evidence of disease activity) during follow-up as defined by:
3 months confirmed EDSS (Expanded disability status scale) progression confirmed relapse new/enlarging T2-hyperintense lesion on MRI (Magnetic resonance imaging) any Gd-enhancing lesion on MRI |
through study completion, on average at least 2 years | |
Secondary | Efficacy of treatment defined by EDSS | EDSS change and EDSS improvement will be considered. EDSS improvement defined as confirmed improvement after 3 months | through study completion, on average at least 2 years | |
Secondary | Efficacy of treatment defined by the annualized relapse rate | calculated as number of relapses per year | through study completion, on average at least 2 years | |
Secondary | Efficacy of treatment defined by the number of new T2 lesions | calculated as cumulative number of new T2 lesions | through study completion, on average at least 2 years | |
Secondary | Efficacy of treatment defined by the number of Gd-enhancing lesions | calculated as cumulative number of GD-enhancing lesions | through study completion, on average at least 2 years | |
Secondary | Efficacy of treatment defined by multiple sclerosis functional composite (MSFC) change | based on summed up Z-scores for individual measures (SDMT, 9 HPT, 25 FWT) | through study completion, on average at least 2 years | |
Secondary | Efficacy of treatment defined by Hamburg quality of life scale in MS (HAQUAMS) | based on HAQUAMS sum score ratings (values between 1 and 5) | through study completion, on average at least 2 years | |
Secondary | Efficacy of treatment defined by the Percentage Brain Volume Change (PBVC) | Brain tissue volume (grey matter, white matter) will be evaluated on T1 weighted images to compute absolute percentage brain volume change | through study completion, on average at least 2 years | |
Secondary | Efficacy of treatment defined by grey and white matter atrophy | based on grey and white matter volume change evaluated on T1 weighted images | through study completion, on average at least 2 years | |
Secondary | Rate of AE / SAE including NCI grade 3 and 4 non-haematological toxicities | Safety of treatment defined by the rate of AE / SAE including NCI grade 3 and 4 non-haematological toxicities | through study completion, on average at least 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02549703 -
Mitochondrial Dysfunction and Disease Progression
|
||
Terminated |
NCT02222948 -
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT02293967 -
Mass Balance Study of MT-1303
|
Phase 1 | |
Terminated |
NCT01790269 -
Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod
|
||
Terminated |
NCT01701856 -
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
|
Phase 4 | |
Completed |
NCT00525668 -
Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
|
Phase 1/Phase 2 | |
Terminated |
NCT00398528 -
An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
|
Phase 4 | |
Completed |
NCT00315367 -
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
|
Phase 4 | |
Terminated |
NCT04032171 -
Study of Evobrutinib in Participants With RMS
|
Phase 3 | |
Completed |
NCT01930708 -
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
|
Phase 4 | |
Completed |
NCT03000647 -
Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis
|
N/A | |
Completed |
NCT02205489 -
Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA
|
Phase 4 | |
Completed |
NCT02753088 -
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
|
Phase 3 | |
Recruiting |
NCT01466114 -
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
|
Phase 2 | |
Completed |
NCT01416155 -
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT01244139 -
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
|
Phase 1 | |
Completed |
NCT00559702 -
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
|
Phase 1 | |
Completed |
NCT00493116 -
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
|
Phase 4 | |
Terminated |
NCT01706107 -
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
|
||
Completed |
NCT01943526 -
Ireland Natalizumab (TYSABRI) Observational Program
|